.png)
The Pharma Letter Podcast
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
The Pharma Letter Podcast
Breakthroughs in MASH, with 89bio CEO
•
With 89bio chief executive Rohan Palekar and VCU Health professor Arun Sanyal
•
Season 1
•
Episode 28
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.
It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.
One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar.
We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.
.png)